US FDA grants priority review and breakthrough therapy designation to AstraZeneca's sBLA for Imfinzi to treat patients ...
AstraZeneca’s supplemental Biologics License Application (sBLA) for Imfinzi (durvalumab) has been accepted and granted Priority Review in the US for the treatment of patients with resectable, early-stage and locally advanced (Stages II, III, IVA) gastric …